ISSN 0974-3618 (Print)
0974-360X (Online)
www.rjptonline.org

REVIEW ARTICLE

A Review on Gouty Arthritis

Manjuladevi. K*, R. Subhash Krishnan, P. Rahini
Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies (VISTAS), P.V. Vaithiyalingam Road, Velan Nagar, Pallavaram, Chennai, Tamilnadu-600117
*Corresponding Author E-mail: **mdevi.sps@velsuniv.ac.in, munchpharma@gmail.com**

ABSTRACT:
Gout is the inflammatory disease which is characterised by the deposition of the Mono Sodium Urate in joints. The joint infection is quickly reassured by Non-Steroidal Anti-inflammatory Drugs. The most common symptoms are pain, redness, and swelling. Gout is primarily detected by recognition of the signs and symptoms of Mono Sodium Urate crystals clumps together in the joints especially in phalanges. The major risk factor occurs in young people because of heavy alcohol intake and they may cause the major symptoms. Metabolism of purine in the liver can produce acute as well as chronic conditions of gout. Hence it is considered by repeated; throbbing attacks of severe arthritis the treatment for gouty arthritis are classified into by their types chronic and acute. The prevalence of gout is over comes around 1000 persons. When compared to woman, the action of gout is high in men. Chronicity might be an aspect of inflammatory disease. It produce unrelieved swelling that follows continual attacks of inflammatory disease. Acute gouty arthritis can be managed by using NSAID's and physical exercise and chronic gout can be managed by physician advisable drugs. Pharmacological management of hyper-uricemia in arthritis is mostly terribly successful. Main cause for the treatment malfunction is due to the reduced actions, and patient education improves observance.

KEYWORDS: Gout, arthritis, Mono Sodium Urate, Hyper-uricemia, uric acid crystals

INTRODUCTION:
Gout is a disease where Mono Sodium Urate (MSU) gets accumulated in synovial fluid and other tissues and multiple areas in the bones. It is the most debilitating disease [1]. Accumulation of mono sodium urate crystals forms inflammatory conditions in a body. Hyper-uricemia is one of bacterial deficiency in gout [2-3]. Mono Sodium Urate crystals can accumulate uric acid crystals in all tissues and nearby the joints. It is detected by recognizing the characteristic of MSU crystals by fluid joint. NSAIDS or colchicines are used to cure acute joint swelling fastly. The main objective in controlling of gout, by using the reduced SUA levels drugs [4-5].



Fig 1: The image shows the uric acid crystals and inflamed joints [6]

Types of gouty arthritis:
1. Acute Gouty Arthritis
2. Chronic Gouty Arthritis

Symptoms:
Typical symptoms are: Pain in the joints, swelling on the joint, Redness in the joint, Warming sensation around the joints, Stiffness, Fever, Tophi-means a small white chunk appears on the skin [7-9].

Causes:
Gout happens because of the gathering of crystals of salt within the joints. They cause inflammation of the tissues of the joint. This accumulation of the salt crystals

Received on 21.01.2019 Modified on 29.03.2019
Accepted on 30.05.2019
Research J. Pharm. and Tech. 2019; 12(11):5583-5588.
DOI: 10.5958/0974-360X.2019.00967.3

happens once you have hyper-uraemia or way over acid in your blood. Being overweight may additionally incline one to high acid levels. Regular use of some medicines like anodyne or diuretics may additionally cause acid levels to rise. High blood pressure or high pressure may additionally cause the acid levels to rise in some cases. In some cases, an abrupt loss of weight may additionally raise the acid levels [10-11].



Figure 2: The Image shows the normal toe and gouty toe [12]

Risk factors:

Risk factors are overweight, consumption of alcohol, elevated Blood Pressure, impaired renal function. Sodium chloride co-transport diuretics, salicylic derivative of aspirin, vitamin B3, immune suppressive, anti-tuberculosis drugs are raised SUC which may also cause gout. Some infections may leads to increase the uric acid secretion in blood such as leukaemia, lymphoma, and haemoglobinopathy. Desiccation, damage to the joint, fever, too much intake of food, high consumption of alcohol, and during surgery precipitation of gouty attack might be occur in patients [13-15].

Epidemiology of gout:

In the general population there is 1-4% of incidence of gout in general prevalence. It happens in 3 to 6 percent in men and 1 to 2 percent in women in western countries. In some countries, universality might expand up to 10 percentages. In men and women generality grows up to 10 percent and 6 percent. The statistical data shows that the people suffering from gout are about 2.68 per 1000 peoples per year approximately. Predominantly men are affected more than women. The major reason for the increase in gout disease is due to the shortage of dietary source, insufficiency in physical workouts [16]. Three Indian studies indicate that about 65% of patients are affected by gout in India. In men (5-27 per 1000 men). It rarely occurs in children and women before menopause.



Fig 3: The Images shows the prevalence of gout in men and women [17]

Diagnosis:

Gout is most debilitating disease most of the patients reports pain in the affected areas, especially in between joints of metatarsal and phalanges. The mono sodium urate crystals clumps in a joints which cause tophus and diagnosing can be done by aspirating needle in the pathological area lab investigation of Serum Uric Crystals (SUC) [18-21] Sometimes patients with a classic history and symptoms of urarthritis are often with success treated and plausible to possess urarthritis while not undergoing centesis. However establishing a firm identification continues to be desirable since other. Circumstances will imitate urarthritis these represents additional crystal-induced inflammatory disease known as pseudo gout, urate crystals in a particular area can be detected by the X-ray and other diagnosing methods like MRI [22]. By detecting tophus using MRI has less strength for visualise [23-24]

Laboratory diagnosis:

Elevated level of uric acid in the serum [25]. Hyperuricemia is a poor indicator for the diagnosis of gout and with normal serum levels the disease it could be diagnosed [26]. The regular diagnosis of gout is the

estimation of MSU crystals in synovial fluid aspirate using polarized light microscopy. While using the compensator the diagnostic yield is better. A microscopic studies used for distinguishing the crystals among particular uric crystal [27]. Withdrawn sample can be diagnosed within 6Hrs. Even Though, they can be observed within a day it should be kept refrigerated at 4 ℃ and then placed under the microscope [28]. In a acute conditions patients affected by leucocytosis and polymorphs [29]. Investigation of amount of uric acid in urine over 24 hours is helpful in evaluating the etiology of hyperuriceamia in gout patients. Urinary uric acid of more than 800 mg/24 hours shows that such patients have developed production of uric acid, thus they excrete a large quantity of uric acid [30].

Radiological diagnosis:

For clinical practice gout can be detected by conventional radiology, but it is not very helpful in early stages for diseases [31]. Radiographic alternatives may remain unchanged for 10 years [32]. During the initial phases of gout, visualized pictures are commonly shows heberden's node in the phalanges and tophus are seen [33].

The main characteristics of radiographic are;

1. Tophus are periarticular soft tissue node [34-35]
2. Joints becomes ankylosing, thus bones become immovable [36]
3. Bone ulceration are typical. The intraarticular damages are seen possibly [37]. There are genesis of tophi in the bones and joints [38].
4. Irregular proliferating bone spicules are seen [39].
5. The sensitivity of radiography results (31%) when it is low and (93%) when it is high [40].

CR is commonly obtainable by cheap, quick and standard to the patients [41]. The type of gout contains uric acid crystals for bone erosions as well as the addition of distal interphalangeal joints with joint space narrowing [42].

Pathogenesis of acute gouty arthritis:

The main reason for the gout is accumulation of uric acid crystals in the joints. and thus the accumulation of uric acid activates the inflammatory mediators like cytokines. This interface ends up in hyperbolic IL-8in phagocytes leading to the establishment of neutrophils [43-44]. Pathologic process of urearthritis also requires preliminary establishment of monocytes and mast cells continued by neutrophils. Before the primary attack of gouty arthritis, macrophages deluge the UA crystals. Good distinguished macrophages have the aptitude to holding these crystals which not induce and associates inflammatory response. Whereas less-differentiated monocytes turn out per amounts of tumour necrosis factor, beside epithelium activation following bodily process of salt crystals [45-46]. Because of the chemotaxis of the neutrophil and other inflammatory mediators in the affected areas cause vasodilations and increase more endothelial gaps and more macrophages and lymphocytes accumulates in the affected area and cause inflammation [46-47].

Pathogenesis of chronic gouty arthritis:

Chronicity can be characterized as inflammatory disease. Due to chronic inflammation it may lead to repeated arthritis attacks. Chronic inflammatory disease indicates by chronic inflammation, gristle harm, cartilage damage and uric acid development. Appearance of salt crystals within the animal tissue which ends up in stimulating cartilage cell to provide swelling of cytokines, gas and matrix metalloproteases resulting in cartilage harm [48-49].

The Disease Stages of Gout:

It is essential to know about its four segments and symptoms. The upcoming reports might to be useful.

Asymptomatic Hyper-uricemia:

The serum urate levels in this step were considered as higher than 6.8mg/dl.

Acute Gouty Attacks:

At greater serum uric acid stages, Mono Sodium Urate (MSU) precipitates out of the serum and is dumped as crystals in the joints or tendons causing inflammation on the local area [50].

Inter-critical Periods (interval between acute attacks):

Throughout this stage, some patients might complain of heaviness owing to slight gouty neuropathy or due to lesser grade inflammation. It is necessary to point out the prominence of non-pharmacological events (diet and exercise), and impending prophylactic use of serum uric acid-lowering agents is to diminish the repeated occurrence of upcoming flares. When the patient attains the ending stage; there is tenacious and unrestrained hyper-uricemia or frequent incidents of highly throbbing attacks. Chronic gout normally includes a poly-articular performance that varies from mono-articular disease. Minor joints like the fingers and toes are gradually affected. Tissue stores of urate crystals can continue in chronic hyper-uricemia, permitting aggregates of MSU that seems to be as tophi in unusual locations (i.e., helix of the ear, extensor surface of the forearm, knees, Achilles tendon, and frequently at the sites of friction and trauma.). There might be misdiagnosing of the condition as rheumatoid, psoriatic, or septic arthritis in this step.

Prevention:

Prevention body fluid urate–lowering medical aid got to be initiated to forestall recurrences. In persons with a history of inflammatory disease and anybody of the following: a minimum of two flares annually (one annually in persons with chronic pathology stage a combine of or greater), tophus, or a history of pathology. Serum rate have to be compelled to be compelled to be right all the way down to a target of not up to five to six mg per decilitre (297 to 357 µmol per L), wishing on the crystal and tophaceous burden [51] ancient body fluid salt levels do not exclude the designation of gouty arthritis. They should be monitored sporadically to assess preventive medical care in patients with repeated urarthritis and a history of elevated salt levels [52]. Urate-lowering medical care ought to be continued for 3 to 6 months when a flare if there aren't any current symptoms. Medical care ought to continue indefinitely if there are a unit current signs or symptoms (e.g., one or additional tophi on examination).

TREATMENT OF GOUT AND HYPER-URICEMIA:

Treatment of Acute Gouty Arthritis:

Intense urarthritis will be a self-limiting condition typically enduring lessening than 14 days, be that as it may, treatment ensures relief from discomfort and rates mending. The IV sedation treatment is started, the quicker the response. As urarthritis is likely going to repeat, giving sufferers an offer of Non-steroidal Anti-inflammatory Drugs or colchicines to begin treatment on the beginning of the progressive scene is critical. The pillar of treatment over the span of the partner in nursing intense unwell assault is that the administration of non-steroid mitigating drug (Non-steroidal Anti-inflammatory Drugs), colchicines, or corticosteroids relying on the comorbid states of the influenced individual [53]. The fundamental standards of gout treatment are: (1) end intense attack as immediately and tenderly as could be expected under the circumstances, (2) anticipate repeat of intense gouty joint pain, (three) spare you or invert cerebral pains coming about because of affidavit of monosodium urate inside the joints, kidneys, or somewhere else, (four) avert or inverse related conditions alongside weight issues, hyperlipidemia, or hypertension, (five) keep the arrangement of uric corrosive urolithiasis. The medication of inclination for intense strike in many patients may be a Non-steroidal Anti-inflammatory Drug outfitted that there had been no contraindications. Cyclooxygenase-2 especially specific inhibitors are no doubt similarly successful as traditional Non-steroidal Anti-inflammatory Drugs, be that as it may, have substantially less concise era gastrointestinal poisonous quality [54]. Calming drugs should be steadily decreased when change happens. The second decision sedate is colchicines as a result of its thin recuperating file [55]. Colchicines related passing from 1985to 1997 [56]. The determination of Non-steroidal Anti-inflammatory Drug versus colchicines depends on man or lady evaluation of cardiovascular, gastrointestinal and renal hazard components. The Yankee connection of Poison control Centres harmful exposure framework recorded [57]. Because of its narrow therapeutic margin, intravenous colchicines are no additional prescribed. Oral colchicines are additional great when managed inside the initial 24 hours after the beginning of an intense assault before phagocytosis builds up itself. An in vogue oral regimens zero.5 mg every hour or 1.Zero mg at regular intervals till torment lightening or side results (vomiting or lose bowels) happen, or until the point when a most extreme of 6 mg is taken (anyway not as much as the measure of colchicines in individuals with renal inadequacy and in the elderly). In any case, as much as 80% of sufferers can't endure the most astounding quality dosage attributable to gastrointestinal side outcomes. An advantageous elective approach is to include low dosages of oral colchicines (zero.6 mg qd– offer) as an aide to another higher-endured number one cure approach (Example: Non-steroidal Anti-inflammatory Drugs). The organization of low everyday dosage of colchicines gives ground-breaking prophylaxis contrary to also intense attack [58]. Corticosteroids have been recommended while colchicines and Non-steroidal Anti-inflammatory Drugs are futile or are contraindicated all through the gouty attack. Intra-articular corticosteroids are for the most part saved for sufferers enduring strikes of one or extensive joints who likewise had contraindication or prejudice to Non-steroidal Anti-inflammatory Drugs or colchicines. In patients with poly-articular gout in whom different medications are hard, foundational corticosteroids are an option. Oral prednisolone (20– 30 mg/day as a matter of first importance, at that point decrease the measurements dynamically) or identical is likewise great [59]. High measurements of steroids had been specified to be related with better expenses of bounce back gouty attack.

Treatment of chronic gouty arthritis:

Gout is portrayed by rehashed, difficult assaults of intense fiery infection. In the event that left untreated, could end up incessant and tophaceous statements could prompt harming joint pain and loss of joint work. The pharmacologic treatment of hyper-uraemia in gouty joint inflammation is for the most part unpleasantly viable. The most explanation behind treatment disappointment is poor consistence, and patient instruction enhances consistence. Patients should be instructed that medicament or uricosuric drug don't include any part inside the treatment of the intense debilitated assault, which salt bringing down solution don't have pharmaceutical properties. pharmaceutical wont to bring

down substantially fluid body substance salt square measure coming to downsize serum salt level to underneath as far as possible (generally set at < vi mg/dl for non-tophaceous and < 5mg/dl for tophaceous gouty joint pain patients). Urate-bringing far-fetched down to be agreeable [60]. Rehash is possible if treatment is irregular or is pulled back once evident sensible administration [61-62]. Current confirmation doesn't bolster treating admirably hyper-uraemia [63]. Therapy might be a long run responsibility and patients World Health Organization have had just a single or 2 intense scenes square measure.

CONCLUSION:

To understand gouty arthritis, and consequently to manage it, has been a challenge to the talent of physicians on the history of drugs. In summary, we have identified a basic treatment and prevention of acute gouty arthritis and chronic gouty arthritis. The better understanding of the pathogenesis of acute gouty arthritis and chronic gouty arthritis will lead to a further option for other treatments.

REFERENCE:

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63:3136–41.
2. Dalbeth N, Merriman TR, Stamp LK. Gout Lancet 2016;388(10055):2039–52.
3. Emmerson BT. The management of gout. New Engl J Med 1996;334 (7):445–51.
4. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouriceamic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66(8):1056–8.
5. Singh JA. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol: Practical Rep Rheum Musculo skelet Dis 2014; 20(3):172–4.
6. https://samadimd.com/common-diseases/what-is-gout
7. Merck Manual. Gout. Accessed May 8, 2012.
8. eOrthopod. Gout. Accessed April 29, 2012.
9. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999 Feb 15;59(4):925-34. Review. PubMed PMID: 10068714.
10. Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364(5):443-452.
11. Tikly M, Makan K. Gouty arthritis: an approach for general practice. South African Family Practice. 2013;55(4):307-312.
12. https://www.hss.edu/conditions_gout-risk-factors-diagnosis-treatment.asp
13. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004.
14. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093.
15. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008;336: 309.
16. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: Prevalence, Incidence and Risk factors. Nat Rev Rheumatol 2015;11 (11):649–62.
17. https://elbiruniblogspotcom.blogspot.com/2011/10/cdc-arthritis-data-and statistics_14.html
18. O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence oftophaceous gout. Mayo Clin Proc 1975;50: 227-8.
19. Agudelo CA, Schumacher HR Jr. The synovitis of acute gouty arthritis: A light and electron microscopic study. Hum Pathol1973; 4: 265-279.
20. Yu KH. Intra articular tophi in a joint without previous gout attack. J Rheumatol 2003; 30: 1868-70
21. Rouault T, Caldwell D S, Holmes EW. Aspiration of the asymptomatic Metatarsophalangeal joint in gout patients and hyper-uricemic controls. Arthritis Rheum 1982; 25: 209-12.
22. Yu KH, Luo SF, Tsai WP, Huang YY. Intermittent elevation of serum urate and 24-Hour urinary uric acid excretion. Rheumatology 2004; 43: 1541-5.
23. Bloch C, Hermann G, Yu TF. A radiological revaluation of gout: a study of 2,000 patients. Am J Roentgen 1980; 134:781-7.
24. Chen CK, Yeh LR, Pan HB, Yang CF, Lu YC, Wang JS, Resnick D. Intra articular gouty tophi of the knee: CT and MRi.
25. Dincer H.E., Dincer A.P., Levinson D.J. Asymptomatic hyperuricemia: to treat or not to treat. Clevel Clin J Med. 2002;69(8):594. 7, 600-2 passim.
26. Badulescu M., Macovei L., Rezus E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942–945. [PubMed]
27. Underwood M. Diagnosis and management of gout. BMJ (Clin Res Ed) 2006;332(7553):1315–1319.
28. Pascual E., Tovar J., Ruiz M.T. The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis. 1989;48(12):983 985. [PubMed]
29. Strasinger S.K., Di Lorenzo M.S. F. A. Davis Company; 2008. Urinalysis & body fluids.
30. Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40 (1):37 42. [PubMed]
31. Fernandes EA, Bergamaschi SB, Rodrigues TC, Dias GC, Malmann R, Ramos GM, et al. Relevant Aspects of imaging in the diagnosis and management of gout. Revista brasileira de reumatologia.2016.
32. Rettenbacher T., Ennemoser S., Weirich H., Ulmer H., Hartig F., Klotz W. Diagnostic imaging of Gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol. 2008; 18(3):621 630. [PubMed]
33. Namas R., Meysami A., Siegal D., Rubin B. Gout and ultrasound: the disease of kings and the queen of imaging. Gout Hyperuricaemia. 2014; 1:94–100.
34. Bloch C., Hermann G., Yu T.F. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol. 1980;134(4):781–787. [PubMed]
35. Malghem J, Vande Berg B, Lecouvet F. Goutte d'hier et d'aujourd'hui. Imagerie de l'appareil musculo-squlettique: Textes choisis. Montpellier (France): Sauramps Medical; 2011. p. 35 44.
36. Omoumi P., Zufferey P., Malghem J., So A. Imaging in gout and other crystal-related arthropathies. Rheum Dis Clin North Am. 2016;42(4):621–644. [PubMed]
37. Martel W. The overhanging margin of bone: a roentgenologic manifestation of Gout. Radiology. 1968;91(4):755–756. [Pub Med]
38. Gentili A. Advanced imaging of gout. Semin Musculo skelet Radiol. 2003;7(3):165 174. [PubMed]
39. Choi M.H., Mac Kenzie J.D., Dalinka M.K. Imaging features of crystal-induced arthropathy. Rheum Dis Clin North Am. 2006;32(2):427–446. viii. [PubMed]
40. Gentili A. The advanced imaging of gouty tophi. Curr Rheumatol Rep. 2006;8(3):231 235. [PubMed]
41. Durcan L., Grainger R., Keen H.I., Taylor W.J., Dalbeth N. Imaging as a potential outcome measure in gout studies: A systematic literature review. Semin Arthritis Rheum. 2016; 45(5):570 579. [PubMed]
42. Dalbeth N., Clark B., McQueen F., Doyle A., Taylor W. Validation of a radiographic damage index in chronic gout.

Arthritis Rheum. 2007;57(6):1067–1073. [PubMed]
43. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappa transcription factors play central roles in interleukin-8 expression stimulated by mono Sodium Urate monohydrate and calcium pyrophosphate crystals in monocytes cells. Arthritis Rheum 2000; 43 (5):1145–55.
44. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical Management of inflammation in acute gouty arthritis. J Clin Rheumatol: Practical Rep Rheumat Musculoskelet Dis 2013;19(1):19–29.
45. Busso N, Ea HK. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo 2012;63(4):230–7.
46. Ea H.K. Mechanisms of gout inflammation. Presse Med. 2011;40(9 Pt 1):836 843. [PubMed]
47. Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465–1479. [PubMed]
48. Grassi W, De Angelis R. Clinical features of gout. Reumatismo 2012;63 (4):238–45.
49. Gonzalez EB. An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol 2012;31(1):13–21.
50. Chen, Lan X. Schumacher, H Ralph. "Gout: An Evidence-Based Review". JCR: Journal of Clinical Rheumatology: October 2008—Volume 14—Issue 5S—pp S55-S62.
51. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627): 1854-1860.
52. Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012;3(6):271-286.
53. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, et al. HLA B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
54. Rubin BR, Burton R, Navarra S, Antigua J, LondonoJ, Pryhuber KG, Lund M, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: arandomized controlled trial. Arthritis Rheum 2004; 50: 598-606.
55. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M Yu et al. Does colchicines work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17: 301-4.
56. Mullins ME, Carrico EA, Horowitz BZ. Fatal cardiovascular collapse following acute colchicine ingestion. J Toxicol Clin Toxicol 2000; 38: 51-4
57. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicines for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol2004; 31: 2429-32.
58. Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol 1997;24: 1364-
59. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329-36.
60. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrolles with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31:1575-81.
61. Scott JT, Loebl WY. Withdrawal of allopurinol in patients with gout. Adv Exp Med Biol 1974; 41: 577-9.
62. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246-8. Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978; 88: 666-70.
63. Campion EW, Glynn RJ, De Labry LO. Asymptomatic hyperuricemia: Risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6.